CP-20961

CAS No. : 35607-20-6

(Synonyms: Avridine)

Price and Availability of CAS No. : 35607-20-6


Size	Price	Stock
5mg	$103	In-stock
10mg	$175	In-stock
25mg	$360	In-stock
50mg	$576	In-stock
100 mg		Get quote
200 mg		Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. :	HY-107634
M.Wt:	667.19
Formula:	C43H90N2O2
Purity:	>98 %
Solubility:	DMSO : 10 mg/mL (ultrasonic;warming;heat to 80°C)

Introduction of 35607-20-6 :

CP-20961 is an interferon inducer. CP-20961 is a potent synthetic non-immunogenic adjuvant that induces arthritis^[1]^[2]^[3]. In Vivo:Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

CP-20961 can be used in animal models to model arthritis and immunomodulation. After animals were injected with CP-20961, the development of arthritis followed a time course identical to that of animals injected with FCA (HY-153808). Disease onset occurred between days 11 and 12 and was already quite advanced by day 16. Toxicity studies showed that mortality did not occur until doses of 200 mg/kg or higher were used^[1]^[2].

1. Induction of Acute/Chronic Polyarthritis^[1]

Background

CP-20961 functions like a Freund's-type adjuvant in inducing polyarthritis by activating the immune system and enhancing the antigen-specific immune response.

Specific Modeling Methods

Rat^[1]: Lewis • Male • male • 235-250 g
Administration: 50 mg/mL (0.2 mL) • subplantar injection • every other day for 16 days

Note

Suspension in a solution of 20 mg CP-20961 in 0.4 ml mineral oil heated and cooled.

Modeling Indicators

Morphological changes: Developed marked inflammatory reaction in the form of diffused erythematous swelling of one or several paws, soon evolved into a more indurated erythema and crippling deformities.

Pathology changes: All of the joints histologically demonstrate intense destruction, profound pannus formation and exuberant periosteal new bone formation. There was a great deal of intense activity of fibroblasts and osteoclasts, primarily adjacent to joints or at tendinous attachments.

Opposite Product(s): Freund's complete adjuvant (FCA) (HY-153808)

2. Induction of Immune Response^[2]

Background

CP-20961 enhanced antibody responses to sheep red blood cells, increased the immune response to various vaccines, and stimulated antitumor host defenses.

Specific Modeling Methods

Rat: Outbred CFW and DBA/2 • female • 8-16 weeks old
Administration: 10 mg/kg • ip • 7, 3 or 1 days before challenge with ip L. monocxtogenes

Note

CP-20961 can be initially dissolved in 0.3 mL of ethyl alcohol. Add Tween 80 (0.1 mL) and combine with the mixture with 4.6 mL of soy bean oil lipid emulsion before modeling.

Modeling Indicators

Metabolism changes: Serum cortisol levels in rats ↑.

Mortality change: Mice infected with Bacillus Calmett-Guerin (BCG) showed no mortality with L. monocytogenes.

Your information is safe with us.

Salutation:

Country:

Customer:

Company Name:

Email:

Requested quantity:

Remarks:

CP-20961

Your information is safe with us.

Inquiry Online